特一药业(002728) - 2023 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2023 reached ¥1,067,212,110.88, representing a 20.38% increase compared to ¥886,570,938.60 in 2022[20]. - The net profit attributable to shareholders was ¥253,175,789.62, marking a 42.07% increase from ¥178,204,104.28 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥249,012,081.13, which is a 43.61% increase from ¥171,371,215.85 in 2022[20]. - Basic and diluted earnings per share were both ¥0.77, up 35.09% from ¥0.57 in 2022[20]. - The weighted average return on net assets increased to 16.57%, compared to 13.98% in the previous year[20]. - The company reported a total revenue of 1,067.21 million yuan in 2023, representing a year-on-year increase of 20.38%[42]. - The net profit attributable to shareholders reached 253.18 million yuan, reflecting a year-on-year growth of 42.07%[42]. - The company achieved a net profit of ¥253,175,789.62 for the fiscal year 2023, with a distributable profit of ¥227,586,694.16 after statutory surplus reserve allocation[159]. Cash Flow and Investments - The net cash flow from operating activities decreased by 46.58% to ¥198,557,705.41 from ¥371,658,160.26 in the previous year[20]. - Operating cash inflow decreased by 2.64% to ¥946,324,466.30, while cash outflow increased by 24.56% to ¥747,766,760.89, resulting in a net cash flow of ¥198,557,705.41, down 46.58%[63]. - Investment cash inflow rose significantly by 81.82% to ¥73,515,945.72, while outflow increased by 10.63% to ¥159,046,533.57, leading to a net cash flow of -¥85,530,587.85[63]. - Financing cash inflow increased by 45.32% to ¥1,109,460,426.76, while outflow rose by 40.51% to ¥1,214,902,277.03, resulting in a net cash flow of -¥105,441,850.27[63]. - Cash and cash equivalents increased by only ¥7,585,267.29, a decline of 95.46% compared to the previous year[64]. Assets and Liabilities - Total assets at the end of 2023 were approximately ¥2.51 billion, a decrease of 1.30% compared to the end of 2022[21]. - Net assets attributable to shareholders of the listed company increased by 43.30% to approximately ¥2.01 billion at the end of 2023[21]. - Total assets included cash of ¥647,247,165.22, accounting for 25.76% of total assets, down from 29.06%[66]. - Inventory increased to ¥271,831,790.86, representing 10.82% of total assets, up from 8.18% due to increased sales[66]. - Fixed assets rose to ¥524,538,600.29, accounting for 20.88% of total assets, up from 14.42% due to projects being completed[66]. - Short-term borrowings decreased to ¥306,000,000.00, down 12.71% from ¥633,680,000.00, primarily due to repayments[66]. Research and Development - The company holds 33 invention patents, 22 design patents, and 8 utility model patents as of the end of the reporting period[39]. - The company is focusing on technological innovation and collaboration with research institutions to improve product quality and efficacy[39]. - The company is advancing multiple R&D projects aimed at improving product quality and expanding market share[62]. - R&D investment increased to ¥53,167,141.27 in 2023, up 22.50% from ¥43,401,780.87 in 2022, representing 4.98% of revenue[63]. - The number of R&D personnel increased by 11.52% to 213, with a notable rise in the number of master's degree holders by 50%[62]. Market and Product Strategy - The company focuses on the research, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials[34]. - The company's core product, Cough Relief Tablets, achieved sales of over 1 billion pieces in 2023, contributing significantly to revenue growth[41]. - The marketing strategy includes a shift from a distributor model to direct sales to retail terminals, aiming to expand sales channels[38]. - The company plans to enhance brand awareness and market promotion, which has already led to increased sales of Cough Relief Tablets and other products[42]. - The company aims to expand the market for its core product, the cough remedy, targeting a sales increase in underrepresented regions[100]. Corporate Governance - The company emphasizes strict adherence to corporate governance standards, ensuring that all shareholders, especially minority shareholders, have equal rights and can fully exercise their rights[121]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete and autonomous business system[124]. - The company has established a comprehensive human resources management system, independent of the controlling shareholder, ensuring that all senior management personnel are employed and compensated solely by the company[124]. - The company has implemented effective measures to protect the legal rights of investors and ensure transparent information disclosure, complying with relevant laws and regulations[121][122]. - The company confirms that its governance practices align with the regulations set forth by the China Securities Regulatory Commission, with no significant discrepancies[123]. Environmental Responsibility - The company is committed to environmental protection and has increased investments in upgrading pollution control facilities to comply with stricter regulations[113]. - The company has implemented strict measures to comply with environmental regulations during its operations[180]. - The company has a wastewater treatment capacity of 1,320 tons per day, achieving discharge standards of COD around 20 mg/L, ammonia nitrogen at 0.1 mg/L, total phosphorus at 0.1 mg/L, and total nitrogen at 1.1 mg/L[186]. - The company invested approximately 6.1124 million yuan in environmental governance and protection in 2023, focusing on wastewater and waste gas treatment, solid waste management, and noise control[194]. - The company has achieved a significant reduction in pollutant discharge through continuous technological improvements and increased environmental investment[188]. Employee and Talent Management - The total number of employees at the end of the reporting period was 1,346, with 748 in the parent company and 598 in major subsidiaries[146]. - The company has established a training plan to enhance talent development, ensuring a stable and vibrant workforce[148]. - The company has a structured salary policy based on job value assessment and performance evaluation[147]. - The company has no labor outsourcing applicable during the reporting period[148]. - The company has a total of 8 employees with master's degrees, 228 with bachelor's degrees, and 292 with associate degrees[146]. Shareholder Engagement and Profit Distribution - The company follows a profit distribution policy that mandates at least 15% of the distributable profit to be distributed in cash if the company is profitable[149]. - The proposed cash dividend distribution is ¥5.00 per 10 shares (before tax), totaling ¥182,445,565, which represents 35.26% of the company's distributable profit[160]. - The company has a cumulative distributable profit of ¥517,500,063.81 as of the end of the reporting period[159]. - Independent directors have fulfilled their responsibilities in the decision-making process regarding the cash dividend policy[156]. - The company is implementing a stock option incentive plan, with 400,000 options granted at an exercise price of ¥14.22 per share[163].